Replies to post #227628 on Biotech Values

[DewDiligence]

ANIX starts phase-1 trial for ovarian-cancer CAR-T:

https://www.prnewswire.com/news-releases/anixa-biosciences-announces-treatment-of-first-patient-in-its-ovarian-cancer-car-t-clinical-trial-301605401.html

While CAR-T therapy has shown efficacy in some hematological tumors, reproducing the same results with solid tumors, such as ovarian cancer, has proven challenging. One of the reasons for this difficulty is that effective CAR-T therapy needs a specific antigen to recognize that is only present on target cancer cells in order to avoid negatively affecting healthy cells. The CER-T therapy being evaluated in Anixa's Phase 1 study differs from traditional CAR-T in that it targets the follicle stimulating hormone receptor (FSHR), which research indicates is exclusively expressed on ovarian cells in healthy adult females.